Connect with us


2 Cannabis Stocks to Consider Buying (And 1 to Avoid)

2 Cannabis Stocks to Consider Buying (And 1 to Avoid)



As most of North America goes back to work following shutdowns due to the coronavirus outbreak, one sector that survived the economic weakness was the cannabis sector. The sector was generally seen as essential by various governments due to the medical cannabis aspect while other retailers were forced to close.

The Canadian cannabis sector continues to see sales grow as more retail stores are opened and Cannabis 2.0 products are rolled out. For January/February, sales were roughly C$150 million per month. The country is now on the pace to top C$2 billion in annual sales this year.

In April, the sector now has 1.5x the number of retail stores as recently as November with more stores on the way in the key province of Ontario. In addition, the Cannabis 2.0 rollout continues to provide another boost to sales.

The bigger question for the sector was liquidity as financial markets became less willing to lend to firms in a developing market such as cannabis with the onset of a recession. Yet, despite weak access to affordable capital, the strong sector sales set up the players with excess cash to survive and thrive in this period.

We’ve delved into these Canadian cannabis stocks with two stocks to consider here and one to avoid. Using TipRanks’ Stock Comparison tool, we lined up the three alongside each other to get the lowdown on what the near-term holds for these cannabis players.

Aphria (APHA)

We will start with Aphria, a Canadian cannabis producer with a strong cash balance sheet and a solid operating business. The stock has started a solid rally off the $3 lows due to encouraging signs in the cannabis sector.

The company ended the last quarter with C$600 million in cash on the balance sheet. On the negative side, Aphria did have C$465 million in debt, but the key at this point in the cycle is the liquidity while smaller competitors lack access to reasonable funding.

The company made the recent deal in May to convert C$127.5 million worth of convertible debt by issuing 18.7 million shares for a conversion price of $4.84 per share. The deal saves C$6.7 million in annual interest costs.

Analysts are forecasting FY20 revenues reaching $390 million followed by nearly $500 million in FY21. The stock has a market cap below $1 billion so lots of value exists here.

The stock is one of the cheapest in the Canadian cannabis space and Aphria is one of only a few cannabis companies with a net cash position above C$150 million. The stock rally to $4 appears the start of extended gains as Aurora Cannabis changed the sentiment in the Canadian cannabis sector.

Overall, APHA holds a Moderate Buy rating from the analyst consensus, based on 5 “buy” ratings and 2 “holds.” Shares are selling for $4.19, and the average price target of $5.45 implies about 30% upside potential. (See APHA stock analysis on TipRanks)

Canopy Growth (CGC)

As with a lot of sectors, the rich only got richer during the downturn. In this case, Canopy Growth saw Constellation Brands cash in warrants providing more cash for financing growth.  

The large Canadian cannabis company ended the December quarter with a cash hoard of C$2.26 billion and the C$245 million from the warrants will further boost the balance sheet. The biggest question for Canopy Growth is whether the new management team can drastically cut the cash burn from large EBITDA losses.

The news wasn’t really surprising with the strike price at only C$12.9783 per share for 18,876,901 warrants to purchase Canopy Growth when the stock was trading above C$21.

The warrants equated to 5.1% of the outstanding shares of Canopy Growth placing the Constellation Brands position up to 38.6%. The company owns warrants to purchase another 139,745,453 shares for a controlling position of 55.8%.

With the extra cash, Canopy Growth remains a solid stock to own here at $18. My recommendation has recently held to pick up the stock on weakness as the company looks to grow revenues while substantially cutting the EBITDA losses from the C$92 million in the last quarter. As the company gets closer to breakeven, the stock will regain a lot of the previous interest in the cannabis space that originally drove the stock above $50. (See Canopy stock analysis on TipRanks)

Tilray (TLRY)

The big-name Canadian cannabis company in the opposite position is Tilray The company has limited cash and a highly unprofitable business.

Tilray generated $52 million in Q1 revenues and analysts forecast Q2 revenues of ~$55 million. The big problem is the ongoing large losses. The company plans to get quarterly operating expenses down to $40 million, but Tilray only generates gross margins in the 29% range.

My biggest issue is that Tilray is plugged into a lot of different business with Canadian cannabis, U.S. hemp and international operations causing the large expense base. If the company had the balance sheet of Canopy Growth or Aphria, the spending levels wouldn’t be a problem.

Tilray ended March with $174 million in cash and had to raise $60 million in debt during February before completing an equity offering. Back in March, the company sold 7.25 million shares and warrants for net proceeds of $90.4 million.

Analysts have Tilray losing money for the next couple of years and the market isn’t going to find money-losing cannabis stocks very appealing in this environment. Investors should watch for the Canadian cannabis company to drastically reduce the quarterly EBITDA losses after losing another $21 million in Q1. Once Tilray gets to a position where additional funds aren’t needed, the stock can be removed from the 'avoid' list.

To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Disclosure: No position.

The post 2 Cannabis Stocks to Consider Buying (And 1 to Avoid) appeared first on TipRanks Financial Blog.

Read More

Continue Reading


Guerilla gardening: how you can make your local area greener without getting into trouble

Many people are gardening on land that is not theirs – here are some things to consider to avoid getting into trouble.



What are your rights if you want to become a guerrilla gardener? Goami/Shutterstock

When Richard Reynolds first started gardening around London’s streets, he was so worried he might be arrested that he worked under the cover of darkness. Reynolds was one of the UK’s first modern guerrilla gardeners, a movement that encourages people to nurture and revive land they do not have the legal rights to cultivate.

Gardening, in general, offers physical and mental health benefits. But as many as one in eight British households have no access to a garden or outdoor space of their own.

This issue is particularly pronounced among city dwellers, ethnic minorities and young people. A 2021 survey conducted in England revealed that those aged 16-24 were more than twice as likely to lack access to a garden or allotment compared to those aged over 65.

Quarter life, a series by The Conversation

This article is part of Quarter Life, a series about issues affecting those of us in our twenties and thirties. From the challenges of beginning a career and taking care of our mental health, to the excitement of starting a family, adopting a pet or just making friends as an adult. The articles in this series explore the questions and bring answers as we navigate this turbulent period of life.

You may be interested in:

How community gardening could ease your climate concerns

Three ways to get your nature fix without a garden

How often do you think about the Roman empire? TikTok trend exposed the way we gender history

Guerrilla gardening is a particularly good option for these groups of people. It can involve planting herbs or vegetables for a whole community to enjoy, spreading seeds or plants, tidying weeds, or even something as simple as picking up litter.

But if you’re considering becoming a guerilla gardener, it’s important to understand your rights. Could you be arrested for it? And should you wait until after dark?

Can you be prosecuted?

It’s important to remember that much of the unused or abandoned land that is potentially suitable for guerilla gardening in towns and cities throughout the UK is owned by local councils. Common examples of such locations include broken pavements with missing slabs, wasteland and the central areas of roundabouts.

Although much of this land is already open for the public to walk over, actively gardening on it would become an act of trespass.

The law of trespass sounds scary. However, gardening on this land would be a breach of civil law rather than a crime. This means that most guerrilla gardeners are unlikely to receive a fine or a criminal record.

Landowners do have the legal right to use “reasonable force” to remove trespassers from their land. But, fortunately, it seems most councils have ignored guerrilla gardeners, having neither the time, money or inclination to bring legal action against them.

Colchester Council, for example, were unable to track down the identity of the “human shrub”, a mysterious eco-activist who restored the flowers in the city’s abandoned plant containers in 2009. The shrub returned again in 2015 and sent a gift of seeds to a local councillor.

In other areas of the UK, the work of guerilla gardeners has been cautiously welcomed by local councils. In Salford, a city in Greater Manchester, there is a formal requirement to submit an application and obtain permission to grow on vacant spots in the city. But the local authority tends not to interfere with illegal grow sites.

There seems to be an unwritten acceptance that people can garden wherever they want, given the abundance of available space and the lack of active maintenance. This also offers the additional advantage of saving both time and money for the local council.

You should still be careful about where you trespass though. In some areas, guerrilla gardening can lead to unwelcome attention. During the May Day riots of 2000, for example, guerrilla gardeners were accused of planting cannabis seeds in central London’s Parliament Square.

Gardening at night may draw the wrong attention too, particularly if you are carrying gardening tools that might be misunderstood by the police as threatening weapons.

How can you start?

There are many different types of guerrilla gardening that you could get involved in, from planting native plant species that benefit pollinators and other wildlife to tidying derelict land to create safer places for the local community.

One of the simplest forms of guerilla gardening is planting seeds. Some environmental projects circulate “seed bombs” and others use biodegradable “seed balloons” that are filled with helium and deflate after a day, distributing seeds by air.

Whatever you try, as a guerrilla gardener you shouldn’t harm the environment or spoil other people’s enjoyment of the space around you. Remember that weeds and wilderness have an environmental value too. And think carefully about the species you are going to plant so that you can protect local plants and wildlife.

A man dropping a seed bomb on the ground in front of a grey building.
Some projects circulate seed bombs. Miriam Doerr Martin Frommherz/Shutterstock

The most attractive species to humans might not provide the best home or food for wildlife. Some can even outcompete native plants and drive them towards extinction. Planting certain harmful, invasive or poisonous species like ragwort, knotweed or Himalayan balsam is even prohibited by law.

That said, some guerrilla gardeners have used social media to organise “balsam bashing” events, where people come together to pull up this harmful invasive plant.

Guerrilla gardening takes many forms and can bring great benefits for people and the environment. You’re unlikely to be arrested for planting and growing trees and other greenery in public spaces. But remember that these spaces should be shared with everyone, including your local wildlife.

Ben Mayfield does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Read More

Continue Reading


Fractyl Health’s GLP-1 gene therapy spurs 25% weight loss in obese mice, clinical trials slated for 2024

One of the biggest problems facing the burgeoning class of weight loss drugs is that people must take them day after day, week after week. When the injections…



One of the biggest problems facing the burgeoning class of weight loss drugs is that people must take them day after day, week after week. When the injections of semaglutide — the ingredient in Ozempic and Wegovy — stop coming, so do the benefits. Lost weight is regained.

But researchers at Fractyl Health, a Lexington, MA-based biotech, believe they have a solution to that problem: a one-time gene therapy injected into the pancreas that lets the body make its own GLP-1 agonists in perpetuity.

New data slated to be presented today at a diabetes conference in Germany suggest that obese mice injected with the therapy lost nearly 25% of their body weight after just two weeks, according to a copy of the company’s presentation obtained by Endpoints News.

The results leave many questions unanswered, including how safe and effective the approach will be beyond the first two weeks, although the presentation indicated that such studies are ongoing. Fractyl declined requests for an interview.

The company previously announced plans to begin testing the treatment in people with diabetes and obesity in 2024. It’s a bold step towards moving gene therapy beyond the rare diseases typically pursued by biotech companies.

Randy Seeley

“It’s hard to get people to take injections once a week, and if we can figure out how to do something closer to one and done, that would be a big step for patients,” Randy Seeley, who directs an obesity research center at the University of Michigan School of Medicine, told Endpoints in an interview.

“But how permanent this will be can’t really be answered in a mouse,” he added. Seeley is a consultant to Fractyl, and the company supports research in his lab.

Fractyl was originally just developing the GLP-1 gene therapy for type 2 diabetes. In a diabetic mouse model, human pancreatic islets and human beta cell lines, the treatment significantly enhanced glucose-stimulated insulin secretion, improving blood sugar levels.

GLP-1 needs to act on receptors in the brain for its weight loss effects, and since the therapy is injected directly into the pancreas, the company didn’t expect the diabetic mice would lose weight, Seeley said. But surprisingly, they did, shedding 23% of their mass after four weeks compared to a control group.

Those results spurred the company to test its gene therapy in a diet-induced obesity mouse model. Twenty mice were fed a high fat diet for 25 weeks before half of them got a single injection of the gene therapy while the other half received daily injections of semaglutide.

Both groups of mice began losing weight a day after the injections. Within five days, the mice who got the gene therapy were losing weight faster and shed 24.8% of their body weight after just two weeks, even as they maintained their high fat diet. The mice on semaglutide lost 18.4% of their weight, according to the data presented at the European Association for the Study of Diabetes Scientific Congress.

“The most surprising part of the data is how much weight these animals lose,” Seeley said. “it’s better than semaglutide, and it’s not exactly clear how that occurs.”

Given the uncertain long-term effects of taking GLP-1 drugs for weight loss, a potentially permanent gene therapy approach is sure to raise many questions.

“If you’re taking your once-a-week version, if something goes wrong, we can turn it off and we just take it away,” Seeley said. “But with gene therapy, there’s no way to turn it off. It’s unknown what happens, and so it is going to take both some careful thought.”

Read More

Continue Reading


Trans To Be Banned From Female Hospital Wards In UK

Trans To Be Banned From Female Hospital Wards In UK

Authored by Steve Watson via Summit News,

The UK Health Secretary is to issue a proposal…



Trans To Be Banned From Female Hospital Wards In UK

Authored by Steve Watson via Summit News,

The UK Health Secretary is to issue a proposal to ban trans patients from female hospital wards in the UK, as well as reinstating ‘sex specific’ language in National Health Service materials, according to reports.

The Daily Mail reports that “Steve Barclay will unveil the plans to push back against ‘wokery’ in the health service amid concerns that women’s rights are being sidelined.”

The proposal would see only people of the same biological sex sharing wards, with care coming from doctors and nurses of the same sex, when it comes to intimate health matters.

“We need a common-sense approach to sex and equality issues in the NHS. That is why I am announcing proposals for clearer rights for patients,” Barlcay stated, adding “It is vital that women’s voices are heard in the NHS and the privacy, dignity and safety of all patients are protected.”

He added “And I can confirm that sex-specific language has now been fully restored to online health advice pages about cervical and ovarian cancer and the menopause.”

As we previously highlighted, the word ‘women’ was removed from such materials and replaced with non-gendered terms to be “more inclusive”:

A source close to the Health Secretary told the Telegraph that “The Secretary of State is fed up with this agenda and the damage it’s causing, language like “chestfeeding”, talking about pregnant “people” rather than women. It exasperates the majority of people, and he is determined to take action.”

“He is concerned that women’s voices should be heard on healthcare and that too often wokery and ideological dogma is getting in the way of this,” the source added.


*  *  *

Brand new merch now available! Get it at

In the age of mass Silicon Valley censorship It is crucial that we stay in touch. We need you to sign up for our free newsletter here. Support my sponsor – Summit Vitamins – super charge your health and well being.

Also, we urgently need your financial support here.

Tyler Durden Wed, 10/04/2023 - 05:00

Read More

Continue Reading